Geno Germano is group president of Pfizer’s Global Innovative Pharma Business, the company’s operating unit focused on development, registration, and commercialization of novel, value-creating medicines that significantly improve patients’ lives. In this role, Geno leads a growing global business with market-leading medicines and a robust pipeline in several therapeutic areas including inflammation, cardiovascular and metabolic disease, neuroscience and pain, and rare diseases. He is a member of a member of Pfizer’s Executive Leadership Team. Additionally, Geno co-chairs the Portfolio Strategy and Investment Committee and manages Pfizer’s Global Health and Value function created to demonstrate the value of innovation and support access to Pfizer medicines. Previously, Geno served as president and general manager of Pfizer’s Specialty Care and Oncology business units. Joining Pfizer from Wyeth Pharmaceuticals, Geno served as president of the U.S. and Pharmaceutical business units and was responsible for the U.S. Pharmaceuticals, Biologics, and Vaccines businesses. In addition, he led the global strategy for the Pharmaceutical and Institutional business units. Geno also held various commercial development and strategy positions at Johnson & Johnson companies. Prior to joining the pharmaceutical industry, Geno was a pharmacist, where he first developed his zeal for science that makes a difference for patients. Geno is a member of the G50, an executive group that seeks to promote openness among business leaders and to create economic and social progress in the region. He serves on the board of the Biotechnology Industry Organization (BIO), on the advisory board of the Healthcare Businesswomen’s Association, and as a trustee of the Albany College of Pharmacy where he received his B.S. degree in pharmacy.